ACAD vs VKTX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ACAD · ACADIA Pharmaceuticals$17.11 ▼ 2.73%
VKTX · Viking Therapeutics$24.77 ▼ 4.14%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ACAD -28.4%
- VKTX -28.5%
Head to head
| Metric | ACAD | VKTX |
|---|---|---|
| Price | $17.11 | $24.77 |
| Change today | ▼ 2.73% | ▼ 4.14% |
| Market cap | $2.96B | $3.16B |
| Return, 3 months | -42.3% | -25.5% |
| Return, year to date | -35.9% | -29.6% |
| Return, 1 year | -27.4% | -27.7% |
| P/E (TTM) | 8.1 | – |
| P/B | 2.1 | 5.4 |
| P/E percentile vs own 5y | 55th | 81st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +22.8% | – |
| Net profit growth (YoY) | -25.4% | -101.8% |
| Gross margin | 90.5% | – |
| Operating margin | 10.2% | – |
| Net margin | 30.1% | – |
| Return on equity | 31.4% | -96.4% |
| Analyst target vs. price | +85.7% | +277.6% |
| Analyst buy share | 77% | 94% |
| RSI (14) | 34 | 41 |
| 30-day volatility | 87.3% | 75.0% |
| Max drawdown, 1 year | -46.0% | -42.5% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- VKTX is the largest of the group by market value.
- ACAD has returned the most over the past year.
- VKTX has been the calmest stock over the last 30 days.